Mutual Recognition Agreements (MRAs) promote trade in goods between the European Union and third countries and facilitate market access. These are bilateral agreements designed to benefit industry by facilitating access to conformity assessment. The new agreement extends this extension to certain biological medicines, including immunologicals and vaccines, which no longer need to be inspected once they have been delivered to the territory of the other. This agreement offers strong guarantees for the protection of EU standards and also aims to ensure that technical regulations, standards and conformity assessment procedures do not create unnecessary barriers to trade. The European Union has concluded negotiations for an agreement with Japan to facilitate trade and facilitate access for European companies to the large Japanese market. This agreement, which was signed on 1 January 2002, Japan`s first bilateral mutual recognition agreement entered into force on 1 January 2002. In April 2016, the Good Manufacturing Practices (GMP) Sectoral Annex for medicinal products was amended. It was then agreed in July 2018 that the operational scope of medicinal products would cover product categories such as chemical medicinal products, pharmaceutical active substances, biological and herbal medicinal products, etc., under certain conditions agreed by both parties. The EU-Australia Agreement covers the following sectors 5.
. . .